38 results about "Secreting cell" patented technology

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

The invention provides a method for purifying ovarian progenitor cells and application of the ovarian progenitor cells to in-vitro generation of steroid secretion cells, and belongs to the technical field of biology. The method for purifying the ovarian progenitor cells comprises the following steps: digesting, filtering and washing an ovary, purifying through a magnetic bead or flow cytometry sorting procedure, and screening to obtain the ovarian progenitor cells, a marker used in the purification process is LY6A, LGR5 or PDGFRA (Platelet Derived Growth Factor Receptor A). Experimental results show that the PDGFRA < + > progenitor cells and the LY6A < + > progenitor cells can form androgen synthetic cells for expressing CYP11A1 and CYP17A1; and the LGR5 < + > progenitor cells can only form progestational hormone synthetic cells which express CYP11A1 but do not express CYP17A1.

Methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells are disclosed. The methods can involve stage-specific differentiation from stem cells or stem cell-derived hematopoietic progenitor cells through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.

This application provides an NPQ-IgG2 / Fc fusion protein and its applications. The fusion protein comprises an NPQ polypeptide and a human IgG2 / Fc region. The NPQ-IgG2 / Fc fusion protein has the ability to specifically bind to hepatocyte HEPG2 and insulin-secreting cells INS-1, and after binding to cells, it undergoes endocytosis, activating intracellular signaling pathways. This application also discloses that the NPQ-IgG2 / Fc fusion protein, through multi-target effects including promoting hepatocyte glucose and lipid metabolism and improving pancreatic β-cell function, can be used to treat liver diseases including fatty liver, diabetes, and other metabolic diseases related to glucose or lipid metabolism disorders.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

The present application relates to a kind of monoclonal antibody that can identify human Topo II alpha antigen, secretes cell strain, its preparation method and its use in immunodetection.The above technical solution selects the amino acid of 1301-1531 of Topo II alpha protein as antigen peptide, codon optimization becomes the gene fragment suitable for expression in escherichia coli BL21, and finally the recombinant protein includes Topo II alpha protein fragment and histidine protein label.The recombinant protein is immunized to mouse, is fused by cell, screening and subcloning, and obtains mouse hybridoma cell strain, and the anti Topo II alpha protein monoclonal antibody secreted by the cell strain is obtained.The antibody obtained by the present application has high specificity, sensitivity, and can specifically recognize the cell expressing Topo II alpha protein, and is suitable for immunological detection, especially immunohistochemical detection.

The invention discloses an influenza B virus T3 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T3 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. According to the invention, detection is carried out through ELISpot, and the immunogenicity of the long peptide (SEQ ID NO.1, named as T3) is verified in 21 volunteers. The result shows that the T3 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, and the immune response induced by the T3 in people can reach up to 2870 SFC / 106 PBMC. Therefore, the polypeptide has good immunogenicity and crowd universality, can be used as a specific detection peptide for monitoring the cellular immune level, can effectively activate the T cell immune response of the crowd, and has the potential of being used as a candidate vaccine epitope peptide to be applied to novel vaccine design.

The present invention provides a method and culture medium for inducing the generation of insulin-secreting cells from stem cells using a specific culture medium and method. This method precisely regulates each stage of differentiation, improving differentiation efficiency and yielding more functional insulin-secreting cells. These cells can be used in diabetes research and treatment, providing a valuable reference and application for subsequent diabetes treatments.

The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.

The invention discloses a specific antibody targeting tumor necrosis factor receptor superfamily Factor 7. The specific antibody comprises a heavy chain variable region, and the heavy chain variable region comprises complementarity determining regions CDR1, CDR2 and CDR3 of amino acid sequences shown as SEQ ID No.2, SEQ ID No.4 and SEQ ID No.6. The invention further discloses a detection method of the heavy chain variable region. The specific antibody provided by the invention has high affinity and specificity. The CAR-T cell constructed by adopting the specific antibody can specifically recognize tumor cells, secrete cell factors IFN-gamma and efficiently kill the tumor cells.

The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.

The invention discloses a stomach body three-dimensional organoid culture medium as well as a preparation method and a culture method thereof, and belongs to the technical field of organoid culture. The stomach body three-dimensional organoid culture medium comprises a basic culture medium and a stomach body organoid growth supplement, the stomach body organoid growth supplement comprises a Wnt signaling pathway agonist, an FGF (Fibroblast Growth Factor) family member, a TGF-beta signaling pathway inhibitor, hyaluronic acid and retinoic acid. The invention further discloses a preparation method of the gastric body three-dimensional organoid culture medium and a gastric body three-dimensional organoid culture method. The method can solve the problems that the existing organoid culture technology is difficult to effectively maintain and amplify the stomach organoid with the functional oxyntocytes, and the existing organoid culture technology has unstable pedigree and incomplete structure.

The invention relates to application of intestinal microbial metabolites in preparation of drugs for preventing and treating parasitic infection. The invention discloses an intestinal flora metabolite (desaminotyrosine, DAT), which can be used for enhancing a type 2 immune response and preventing and treating infection of parasites. The DAT is mainly an important phenolic acid product generated by metabolism of flavonoid compounds by clostridium, in a Nipostrongylus brasiliensis (Nb) infection model, the metabolite effectively relieves clinical symptoms of mice and promotes proliferation of Tuft cells during parasite infection, the Tuft cells can secrete IL-25 after being proliferated in mice normally drinking the DAT, and in addition, the Tuft cells can secrete IL-25 after being proliferated in the mice normally drinking the DAT. The Tuft cell-derived IL-25 further activates type 2 innate lymphoid cells (ILC2) to generate type 2 immune factors (IL-4 and IL-13), and proliferation of cluster cells accelerates removal of parasites and reduces intestinal injury. In addition, verification is carried out in a cluster cell knockout mouse, and deletion of cluster cells can accelerate proliferation of the Brazilian strongylus nematode and aggravate intestinal injury. The factors are crucial to anti-parasitic reaction of a human body, and the metabolite has a wide application prospect in preparations for preventing and treating parasitic infection.

An object of the present invention is to provide an approach of removing non-endocrine unintended cells coexisting with insulin-secreting cells obtained by the differentiation. The present invention relates to a method for producing an insulin-producing cell population, comprising the step of treating an insulin-producing cell population obtained by the differentiation from pluripotent stem cells with a PLK inhibitor.

The present invention relates to a method for detecting single cell lactic acid secretion, and specifically provides a method for detecting cell lactic acid secretion, comprising: 1) incubating a fluorescent probe and cells in separate partitions, and 2) detecting the fluorescent signal, wherein the fluorescent signal of the partition where the lactic acid secreting cell is located is weakened. The method of the present application achieves accurate detection of cell lactic acid secretion.

The disclosure relates to genetically modified non-human animals, including mice, in which a diphtheria toxin receptor (DTR) gene is inserted into the endogenous Jchain locus. Also provided are methods of making the animals, and uses of the animals for selective deletion of antibody-secreting cells (ASCs).

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.

The present disclosure provides isolated induced pluripotent stem cells (iPSCs) having an exogenous promoter operably inserted upstream of a translation initiation region of a gene encoding Factor VIII (FVIII) on genomic DNA, the exogenous promoter being capable of driving the gene to secrete FVIII; a composition comprising the cells; and a pharmaceutical composition comprising FVIII-secreting cells induced from the composition.

The invention discloses a method for inducing human adipose-derived stem cells to be differentiated into insulin-secreting cells. The method comprises the following steps: separating and extracting human adipose-derived stem cells from human adipose tissues and enabling the human adipose-derived stem cells to be self-polymerized; placing the auto-aggregated and balled human adipose-derived stem cells in an induced differentiation medium for first-stage induction to obtain a first induced differentiation system; retinoic acid and a transformation factor beta1 are supplemented into the first induced differentiation system, and meanwhile, synergistic induction is performed in combination with near-infrared light irradiation to obtain a second induced differentiation system; and supplementing taurine, beta cytokine, insulin-like growth factors, nicotinamide and a BMPI type receptor kinase inhibitor into the second induced differentiation system, and carrying out synergistic induction through near-infrared light irradiation to obtain the insulin secreting cells. According to the method, the cell differentiation efficiency is remarkably improved, and a new theoretical basis is provided for differentiation from the human adipose-derived stem cells to the insulin secreting cells and application of the human adipose-derived stem cells.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a method for inducing mesenchymal stem cells to differentiate into insulin-secreting cells and application of the method. According to the method, a culture system is regulated and controlled by stages, the glucose concentration is respectively regulated in different induction stages, an NAD + precursor substance, a fatty acid composition and an antioxidant factor are added, and a three-dimensional microcarrier culture mode is combined, so that the cell metabolism state, the oxidation-reduction balance and the space structure are dynamically regulated and controlled. Under the condition of not depending on recombinant protein inducing factors such as Activin A and Wnt3a, the efficient directional differentiation of the mesenchymal stem cells to the insulin-secreting cells is realized. By adopting the method disclosed by the invention, the differentiation efficiency can be improved, the induction period can be shortened, the mature beta-like cells with a stable glucose stimulation dependent insulin secretion function can be obtained, and the method is suitable for induced differentiation and related research application of the human adipose-derived mesenchymal stem cells.

The invention discloses an influenza B virus T2 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T2 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. Verification is carried out through ELISpot, T2 is detected to be positive in six persons, the positive rate is 28.57%, S-T2 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, the highest immune response induced by T2 in the HLA-A2 population can reach 890 SFC / 106 PBMC, and the highest immune response induced by S-T2 in the HLA-A2 population can reach 650 SFC / 106 PBMC. Therefore, T2 and S-T2 can stably induce human T cells to generate immune response, can be used for monitoring the cellular immune level, can effectively activate the T cell immune response of people, and has the potential of being used as candidate vaccine epitope peptide to be applied to novel vaccine design.

The application discloses application of MST1 interfering RNA in promoting in-vitro differentiation of ESCs into insulin-secreting cells, and belongs to the technical field of biotechnology. In the process of in-vitro directional differentiation of rat ESCs into beta cells, the application infects by using an MST1 shRNA lentivirus vector, and indexes are detected and functions are determined by using cell biology and molecular biology methods, and it is found for the first time that the efficiency of inducing ESCs to differentiate into beta cell-like cells can be improved by reducing the expression of MST1. Meanwhile, how MST1 realizes the regulation of beta cell maturation by means of PDX1 in the process of directional differentiation of rat ESCs into beta cells is described, the reason affecting in-vitro maturation of beta cells is discussed, and thus the system of directional differentiation of ESCs into mature beta cells is optimized, which has important significance for obtaining beta cells with normal insulin secretion function in-vitro.

The invention discloses an induction culture medium for directionally differentiating mesenchymal stem cells into insulin-secreting cells. The induction culture medium consists of a differential culture medium I, a differential culture medium II and a differential culture medium III. The invention further discloses an induction method for directionally differentiating the mesenchymal stem cells into the insulin-secreting cells. The induction culture medium for directionally differentiating the mesenchymal stem cells into the insulin-secreting cells is used for carrying out differentiation culture. According to the induction culture medium and the induction method for directionally differentiating the mesenchymal stem cells into the insulin-secreting cells, the intestinal bioelectricity environment is simulated by using electrical stimulation while chemical induction is used, cell contraction is promoted to achieve the effect of simulating movement, and active small-molecule polypeptide of spidermoss is added to protect cell membranes, so that the insulin-secreting cells are directionally differentiated into the insulin-secreting cells. The success rate of original intestinal canal differentiation is improved; and the IPCs differentiation efficiency is improved. The induction culture medium and the induction method have important application value in treating diseases such as diabetes mellitus and the like by clinically applying the MSC.

The invention discloses four antibody secreting cell strains for detecting ChiVMV-TMV viruses, antibodies secreted by the four antibody secreting cell strains and application of the four antibody secreting cell strains and belongs to the technical field of microorganisms, the four cell strains are hybridoma cell strains ChiVMV-a, ChiVMV-b, TMV-1 and TMV-2 respectively and are all preserved in the China Center for Type Culture Collection, and the preservation numbers of the four cell strains are CCTCC NO.C202563, CCTCC NO.C202564, CCTCC NO.C2024407 and CCTCC NO.C2024408 respectively. The specific monoclonal antibodies secreted by the four cell strains are utilized, based on the double-antibody sandwich immunochromatography principle, and through the specific antibody combination and double detection line design, the ChiVMV and TMV virus infections can be distinguished at the same time with high precision and high accuracy in single detection, the tedious process of step-by-step detection in a traditional method is avoided, and the detection efficiency is remarkably improved.

The present disclosure belongs to the field of biological medicines, and relates to an inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells uses human mesenchymal stem cell serum-free culture medium as a substrate and comprises the following components in mass concentration ratios: 20-60 mg / L of bone morphogenetic protein-4, 20-60 mg / L of bone morphogenetic protein-7, 2-8 mg / L of retinoic acid, 2-8 mg / L of resveratrol, 2-8 mg / L of icariin, 2-8 μg / L of benzamide, 2-8 μg / L of chloroplatinic acid hexahydrate, 2-8 μg / L of ethanolamine, 2-10 μg / L of erythropoietin and 2-10 μg / L of vascular endothelial growth factor. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells provided by the present disclosure has a high induction efficiency.

The invention discloses application of temperature-sensitive hydroxypropyl chitin hydrogel in preparation of a medicine for treating intervertebral disc degeneration, and belongs to the technical field of biological medicine. The temperature-sensitive hydroxypropyl chitin hydrogel has good biocompatibility and temperature sensitivity, is liquid in a low-temperature state, quickly forms transparent hydrogel after entering a human body, and can seal a damaged fibrous ring and prevent medicine leakage. The fibroblast has the functions of secreting extracellular matrix and inhibiting inflammation, and can maintain the height and stability of the intervertebral disc and relieve clinical symptoms. The combination of the temperature-sensitive hydroxypropyl chitin hydrogel and the fibroblast can promote the fibroblast to secrete an extracellular matrix, provide a stronger biomechanical function, give full play to the curative effect in a patient with a broken fibrous ring, and fill the gap of leakage type intervertebral disc cell therapy.

The invention discloses an influenza B virus T1 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T1 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. Immunogenicity verification is carried out through ELISpot, T1 is detected to be positive in seven persons, the positive rate is 33.33%, S-T1 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, the immune response induced by the T1 in the HLA-A2 population can be up to 4160 SFC / 106 PBMC at most, and the S-T1 can be up to 990 SFC / 106 PBMC at most. Therefore, T1 and S-T1 can stably induce human T cells to generate immune response, can be used for monitoring the cellular immune level, can effectively activate the T cell immune response of people, and have the potential of being used as candidate vaccine epitope peptides to be applied to novel vaccine design.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.